Tag Archives: semaglutide

Viking, Madrigal, Sanofi, Alnylam, Regeneron Q2 ’26 Earnings; Lilly Invests in KwikPen US Manufacturing Site; Verdiva Doses First Patient in Ph1 VRB-103 Study

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Madrigal Pharmaceuticals, Sanofi, Alnylam, Regeneron, Resilience/Lilly, and Verdiva Bio. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Altimmune Topline Ph2 Pemvidutide AUD Data; GSK Q2 ’26 Earnings; New Pfizer Ph1 Oral GLP-1RA Study; Antag Ph2a GIP Antagonist Study; Salubris Ph2 Lp(a) Study

A series of cardiometabolic-related news items has been observed from Altimmune, GSK, Pfizer, Antag Therapeutics, and Shenzhen Salubris Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Sues Lilly Over DTC Ads; Novartis Q2 ’26 Earnings; Aspen Generic Sema in Canada; Medtrum 300U Patch Pump to Launch in Germany; Hilo Launches Cuffless BP Monitor in US

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Novartis, Aspen Pharmacare, Medtrum, and Hilo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Icosema Launches in China; Medicare GLP-1 Bridge Reaches 100k Patients; Ex-Lilly Exec Joins Zealand; July CHMP Agenda

A series of cardiometabolic-related news items has been observed by Fangzhou/Novo Nordisk, CMS, Zealand Pharma, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Hengrui Ph2 Triple Agonist Study; MindRank Series B; Semaglutide on NEDL; New Foundayo DTC Ad; Endogenex ReCET Enrollment Complete; Ionis/AZ Miss Primary Endpoint in CARDIO-TTRansform; Dr. Reddy’s Halts Sema

A series of cardiometabolic-related news items has been observed by Hengrui, MindRank, Lilly, Endogenex, Ionis/AstraZeneca, and Dr. Reddy’s. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMs

A series of cardiometabolic-related news items has been observed from The Obesity Action Coalition, Hengrui, Terrestrial Bio, Tandem Diabetes Care, and Tufts Health Direct. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo AMAZE 7 and 13 Zenagamtide Studies; New Ph2 UBT251 Study; Vivani Ph1 Sema Implant Study; TWL Virtual Tirzepatide Assessment; Anodyne $12.6M Series A

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Vivani Medical, Top Weight Loss Med, and Anodyne Nanotech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Structure Initiates Pivotal Aleniglipron Studies; MiniMed Flex US Launch; FiberSense CGM CE Mark; FDA Compounding Warning Letters

A series of cardiometabolic-related news items has been observed from Structure Therapeutics, MiniMed, FiberSense, and FDA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Receives MHRA Approval of Wegovy Pill in the UK

Novo Nordisk announced it received MHRA approval of Wegovy Pill (25mg QD oral semaglutide) for adults with obesity and ≥1 weight-related condition. This approval is based on results from the Ph3 OASIS 4 trial (view publication). Below, FENIX provides brief thoughts on how the OUS Wegovy Pill expansion may impact Novo’s business trajectory.

This content is for Read Less members only.

Already a member? Log in here